Markets:

Overview

News

Currencies

International

Treasuries

CorMedix Inc. - Common Stock (NQ:CRMD)

12.04 +0.41 (+3.57%)

Streaming Delayed Price Updated: 1:47 PM EST, Jan 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about CorMedix Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

CorMedix Inc (NASDAQ:CRMD): A Textbook Fit for a High-Growth Stock Screener ↗

December 29, 2025

CorMedix (CRMD) exemplifies a high-growth stock with explosive sales, strong earnings momentum, and robust profitability, fitting a proven investment framework.

Via Chartmill

Why CorMedix Could be the Biopharma Name to Watch Early in 2026 ↗

December 23, 2025

Via MarketBeat

MarketBeat’s Top 5 Rated Small-Cap Stocks ↗

December 22, 2025

Via MarketBeat

Why Is CorMedix Stock Rising Today? ↗

December 18, 2025

CorMedix said that its catheter lock solution showed fewer catheter-related bloodstream infections and secondary hospitalizations in adult dialysis patients in the interim study.

Via Stocktwits

CorMedix Inc (NASDAQ:CRMD) Shows Explosive Growth Metrics in "Little Book" Screen ↗

December 08, 2025

CorMedix (CRMD) shows explosive sales & earnings growth, strong momentum, and a surprisingly low valuation, making it a top growth stock candidate.

Via Chartmill

CorMedix Stock Breaks Out To 2-Month High: Analysts Reset Price Targets After Blowout Q3 And Surging DefenCath Demand ↗

November 13, 2025

Via Stocktwits

Earnings Scheduled For November 12, 2025 ↗

November 12, 2025

Via Benzinga

CRMD Stock Is The Talk Of The Town Today: What’s The Latest 2025 Revenue Forecast? ↗

October 20, 2025

Via Stocktwits

Analyst Expectations For Cormedix's Future ↗

September 09, 2025

Via Benzinga

Talphera (TLPH) Q3 2025 Earnings Call Transcript ↗

November 13, 2025

Talphera (TLPH) Q3 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

CorMedix Q3 Profit Soars As DefenCath Dialysis Demand Exceeds Expectations ↗

November 12, 2025

CorMedix posts strong Q3 results with $104 million in revenue, higher DefenCath sales, and raises 2025 guidance following Melinta integration progress.

Via Benzinga

Pharming Group Posts Upbeat Q3 Results, Joins On Holding, BigBear.ai Holdings And Other Big Stocks Moving Higher On Wednesday ↗

November 12, 2025

Via Benzinga

Cormedix Stock Soars Pre-Market After Earnings Beat, Higher Full-Year Guidance ↗

November 12, 2025

The company now expects pro forma net revenue for the full year in a range of $390 million to $410 million, higher than a Wall Street estimate of $283.66 million.

Via Stocktwits

Topics Earnings

CorMedix Strikes $300M Deal For Melinta Therapeutics, Retail Calls It A ‘Wonderful Acquisition’ ↗

August 07, 2025

Via Stocktwits

CorMedix Inc. (NASDAQ:CRMD) Q3 2025 Earnings: Revenue Beat Offsets EPS Miss ↗

November 12, 2025

CorMedix Inc. (CRMD) Q3 2025 earnings show a revenue beat of $104.3M, but an EPS miss. The stock rose in pre-market trading on strong sales growth.

Via Chartmill

CorMedix Inc (NASDAQ:CRMD) Fulfills Key Growth Stock Criteria from The Little Book ↗

November 11, 2025

CorMedix (CRMD) excels in a proven growth stock strategy, showing massive sales growth, strong earnings momentum, and solid profitability metrics.

Via Chartmill

Top Stocks With Earnings This Week: Plug, Oklo, Circle And More ↗

November 10, 2025

Here's a look at this week's earnings reports that are most likely to be watched by retail investors, including Oklo, Plug and Circle.

Via Benzinga

Halper Sadeh LLC Encourages CorMedix Inc. Shareholders to Contact the Firm to Discuss Their Rights

October 22, 2025

From Halper Sadeh LLC

Via Business Wire

Beyond The Numbers: 4 Analysts Discuss Cormedix Stock ↗

October 21, 2025

Via Benzinga

CorMedix Inc (NASDAQ:CRMD) Fits a Proven Growth Strategy with Strong Fundamentals ↗

October 21, 2025

CorMedix Inc. fits a proven growth investing strategy with explosive revenue growth, soaring profits, and strong analyst revisions, signaling high potential.

Via Chartmill

CorMedix Inc (NASDAQ:CRMD) Identified as a Top Growth Stock Candidate ↗

September 29, 2025

CorMedix Inc (CRMD) identified as a top growth stock using Louis Navellier's strategy, showing explosive revenue growth, soaring earnings estimates, and strong profitability.

Via Chartmill

CorMedix Inc (NASDAQ:CRMD) Embodies a Proven Growth Investing Strategy ↗

September 08, 2025

CorMedix (CRMD) excels in Louis Navellier's growth strategy with massive revenue growth, soaring earnings, and high ROE, making it a top stock to watch.

Via Chartmill

10 Health Care Stocks Whale Activity In Today's Session ↗

September 02, 2025

Via Benzinga

CORMEDIX INC (NASDAQ:CRMD) – A High-Growth Stock Aligned with Louis Navellier’s Investment Strategy ↗

August 18, 2025

Discover how CORMEDIX INC (CRMD) aligns with Louis Navellier’s growth investing strategy, showcasing strong earnings momentum, rapid revenue growth, and high ROE for potential stock gains.

Via Chartmill

Elliott Management Bets Against S&P 500, Nasdaq 100, Nvidia Stock In Second Quarter ↗

August 14, 2025

Elliott Management places new bets against the market in the second quarter, while taking a new long position in Hewlett Packard Enterprise.

Via Benzinga

Topics Stocks

Deal Dispatch: Performance Food Group And Claire's Lead A Week Of Big Auctions, Retail Woes ↗

August 08, 2025

Performance Food rejects offer; Lufthansa drops Air Europa bid; NFL inks deal with ESPN; Claire's files bankruptcy amid retail struggles.

Via Benzinga

Topics Bankruptcy

CorMedix Inc (NASDAQ:CRMD) Reports Strong Q2 2025 Earnings, Beats Estimates and Announces Strategic Acquisition ↗

August 07, 2025

CorMedix Inc (CRMD) reported strong Q2 2025 earnings, beating revenue and EPS estimates, with shares rising in pre-market trading. The company also announced the acquisition of Melinta Therapeutics.

Via Chartmill

Topics Earnings

Important Notice to Long-Term Shareholders of CorMedix Inc. (NASDAQ: CRMD); Maison Solutions, Inc. (NASDAQ: MSS); Napco Security Technologies, Inc. (NASDAQ: NSSC); and Treace Medical Concepts, Inc. (NASDAQ: TMCI); Grabar Law Office is Investigating Claims

July 09, 2025

From Grabar Law Office

Via GlobeNewswire

Important Notice to Long-Term Shareholders of AdaptHealth Corp. (NASDAQ: AHCO); CorMedix Inc. (NASDAQ: CRMD); Napco Security Technologies, Inc. (NASDAQ: NSSC); and Virtu Financial Inc. (NYSE: VIRT): Grabar Law Office is Investigating Claims on Your Behalf

July 02, 2025

From Grabar Law Office

Via GlobeNewswire

CorMedix Analyst Says Investors Could Be Further Rewarded ↗

June 30, 2025

CorMedix boosts Q2 sales forecast as a major dialysis client accelerates DefenCath use, prompting positive analyst coverage and growth outlook.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.